Nightingale Health

Nightingale Health is the global leader in NMR-based metabolomics, quantifying 250 blood biomarkers from a single sample to enable large-scale disease risk detection and prevention. Founded in Helsinki, it completed the analysis of all 500,000 UK Biobank samples, creating the world's largest blood biomarker database. Listed on Nasdaq Helsinki Main Market since March 2025, the company is deploying its technology into Finnish public healthcare in 2026 through wellbeing services counties. It also partnered with Alamar Biosciences to expand into brain health proteomics.